ACHILLES HEALTHYMAGINATION VALIDATION

INTRODUCTION

GE’s healthymagination innovations are validated based on the proven level of contribution towards GE’s healthymagination goals of enabling 15% reductions in cost and 15% improvements in access and quality of healthcare. Innovations are submitted for validation, along with supporting technical documentation, to Oxford Analytica whose independent network of scholar experts uses a predefined scoring system to assess the strength of the evidence supporting the innovation’s claims.

ACHILLES ASSESSMENT

Achilles has been awarded healthymagination validation on cost, access and quality by Oxford Analytica and its external independent experts.

Cost

Academic literature shows Achilles’ potential to reduce cost through better disease management and lower utilisation of healthcare services. For example, Kraemer et al. showed that a sequential approach that uses QUS prior to DXA (as opposed to DXA alone) to diagnose hip fracture could lead to savings as high as 66.7% in total direct medical costs, including diagnosis, hip fracture treatment and bisphosphonate treatment.

Access

Current evidence shows that Achilles has significantly improved access to osteoporotic fracture risk assessment in target markets, namely hospitals and clinics that provide preventative health checks for older adults in Japan. Based on the annual figures reported by the Japanese Osteoporosis Foundation, Achilles’ adoption levels by the institutions using QUS in the country have been been consistently high (33%-35%) between 2005 and 2010.

Quality

QUS provides similar levels of accuracy to DXA in assessing fracture risk, thus showing the potential for similar reductions in the rate of hip fracture (37.2% reduction through DXA). Improvements in quality of care also result from Achilles’ use of non-ionising radiation.

Potential cost savings as high as 66.7% in hip fracture diagnosis, treatment and bisphosphonate treatment

Consistently high adoption levels (33%-35%) by institutions using QUS in Japan

Potential 37.2% reduction in hip fracture rates
ABOUT OXFORD ANALYTICA

Oxford Analytica is a global analysis and advisory firm which draws on a worldwide network of over 1,500 experts to advise its clients on their strategy and performance. It provides seasoned judgment on national and international affairs and independent analysis of global events, trends and their impact to governments, international organisations, financial institutions and multinational corporations. Oxford Analytica has built an international reputation as the industry standard for strategic intelligence and analysis of geopolitical, macroeconomic and social developments worldwide.

Learn more about Oxford Analytica at www.oxan.com